Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Happel, AU; Rametse, L; Perumaul, B; Diener, C; Gibbons, SM; Nyangahu, DD; Donald, KA; Gray, C; Jaspan, HB.
Bifidobacterium infantis supplementation versus placebo in early life to improve immunity in infants exposed to HIV: a protocol for a randomized trial.
BMC Complement Med Ther. 2023; 23(1): 367 Doi: 10.1186/s12906-023-04208-0 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Co-authors Med Uni Graz

Diener Christian

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

INTRODUCTION: Infants who are born from mothers with HIV (infants who are HIV exposed but uninfected; iHEU) are at higher risk of morbidity and display multiple immune alterations compared to infants who are HIV-unexposed (iHU). Easily implementable strategies to improve immunity of iHEU, and possibly subsequent clinical health outcomes, are needed. iHEU have altered gut microbiome composition and bifidobacterial depletion, and relative abundance of Bifidobacterium infantis has been associated with immune ontogeny, including humoral and cellular vaccine responses. Therefore, we will assess microbiological and immunological phenotypes and clinical outcomes in a randomized, double-blinded trial of B. infantis Rosell®-33 versus placebo given during the first month of life in South African iHEU. METHODS: This is a parallel, randomised, controlled trial. Two-hundred breastfed iHEU will be enrolled from the Khayelitsha Site B Midwife Obstetric Unit in Cape Town, South Africa and 1:1 randomised to receive 8 × 10⁹ CFU B. infantis Rosell®-33 daily or placebo for the first 4 weeks of life, starting on day 1-3 of life. Infants will be followed over 36 weeks with extensive collection of meta-data and samples. Primary outcomes include gut microbiome composition and diversity, intestinal inflammation and microbial translocation and cellular vaccine responses. Additional outcomes include biological (e.g. gut metabolome and T cell phenotypes) and clinical (e.g. growth and morbidity) outcome measures. DISCUSSION: The results of this trial will provide evidence whether B. infantis supplementation during early life could improve health outcomes for iHEU. ETHICS AND DISSEMINATION: Approval for this study has been obtained from the ethics committees at the University of Cape Town (HREC Ref 697/2022) and Seattle Children's Research Institute (STUDY00003679). TRIAL REGISTRATION: Pan African Clinical Trials Registry Identifier: PACTR202301748714019. TRIALS: gov: NCT05923333. PROTOCOL VERSION: Version 1.8, dated 18 July 2023.

Find related publications in this database (using NLM MeSH Indexing)

Female - administration & dosage

Humans - administration & dosage

Infant - administration & dosage

Pregnancy - administration & dosage

Bifidobacterium longum subspecies infantis - administration & dosage

Dietary Supplements - administration & dosage

HIV Infections - drug therapy

Randomized Controlled Trials as Topic - administration & dosage

South Africa - administration & dosage

Vaccines - administration & dosage

Find related publications in this database (Keywords)

HIV exposure

South Africa

Live biotherapeutic

Randomised controlled trial

Bifidobacterium

© Med Uni Graz • Imprint